Aliases & Classifications for Oppositional Defiant Disorder

MalaCards integrated aliases for Oppositional Defiant Disorder:

Name: Oppositional Defiant Disorder 12 77 56 6 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050856
ICD10 34 F91.3
UMLS 74 C0029121

Summaries for Oppositional Defiant Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by a pattern of angry mood, defiant behavior and vindictiveness in children and adolescents.

MalaCards based summary : Oppositional Defiant Disorder is related to depression and anxiety, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Oppositional Defiant Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Oppositional defiant disorder (ODD) is listed in the DSM-5 under Disruptive, impulse-control, and... more...

Related Diseases for Oppositional Defiant Disorder

Diseases related to Oppositional Defiant Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 depression 30.9 MAOA SLC6A4 TPH2
2 anxiety 30.5 COMT MAOA SLC6A4 TPH2
3 separation anxiety disorder 30.4 DRD4 SLC6A3
4 traumatic brain injury 30.1 COMT DRD2
5 brain injury 30.1 COMT DRD2
6 bipolar disorder 29.8 COMT DRD2 SLC6A3 SLC6A4
7 stuttering 29.8 DBH DRD2 SLC6A3
8 tic disorder 29.7 DRD2 DRD4 SLC6A3 TPH2
9 conduct disorder 29.6 COMT DBH DRD2 DRD4 MAOA SLC6A3
10 borderline personality disorder 29.5 COMT MAOA SLC6A4 TPH2
11 generalized anxiety disorder 29.2 COMT DRD2 MAOA SLC6A2 SLC6A4
12 disease of mental health 29.0 COMT DRD2 DRD4 MAOA SLC6A2 SLC6A3
13 personality disorder 29.0 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
14 gilles de la tourette syndrome 28.9 COMT DBH DRD2 DRD4 SLC6A3
15 attention deficit-hyperactivity disorder 28.9 COMT DBH DRD2 DRD4 MAOA SLC6A2
16 mood disorder 28.4 COMT DRD2 DRD4 MAOA SLC6A2 SLC6A4
17 alcohol dependence 27.8 COMT DBH DRD2 DRD4 MAOA SLC6A3
18 schizophrenia 27.4 COMT DBH DRD2 DRD4 MAOA SLC6A2
19 pol iii-related leukodystrophies 11.1
20 autism 10.6
21 autism spectrum disorder 10.5
22 pseudobulbar affect 10.3
23 dependent personality disorder 10.2 DRD4 MAOA
24 avoidant personality disorder 10.2 MAOA SLC6A4
25 atypical depressive disorder 10.2 MAOA SLC6A4
26 premature ejaculation 10.2 SLC6A3 SLC6A4
27 dysthymic disorder 10.2 MAOA SLC6A4
28 amphetamine abuse 10.2 SLC6A2 SLC6A3
29 kleptomania 10.2 MAOA SLC6A4
30 delusional disorder 10.2 DRD2 DRD4
31 impulse control disorder 10.2 DRD2 DRD4
32 striatonigral degeneration 10.1 DRD2 SLC6A3
33 heroin dependence 10.1 DRD2 DRD4
34 phobia, specific 10.1 COMT MAOA
35 reading disorder 10.1
36 hematohidrosis 10.1
37 periodic limb movement disorder 10.1 DRD2 SLC6A4
38 serotonin syndrome 10.1 MAOA SLC6A4
39 dystonia 1, torsion, autosomal dominant 10.0 COMT MAOA
40 schizophreniform disorder 10.0 COMT DRD2
41 polysubstance abuse 10.0 COMT DRD2
42 kleine-levin hibernation syndrome 10.0 COMT SLC6A3
43 tardive dyskinesia 10.0 COMT DRD2
44 central nervous system disease 10.0 SLC6A2 SLC6A3 SLC6A4
45 agoraphobia 10.0 MAOA SLC6A2 SLC6A4
46 fibromyalgia 10.0 COMT SLC6A4
47 opioid addiction 10.0 COMT DRD2
48 alcohol-induced mental disorder 10.0 DRD2 SLC6A3 SLC6A4
49 alcoholic psychosis 10.0 DRD2 SLC6A3 SLC6A4
50 opiate dependence 9.9 DRD2 SLC6A4

Graphical network of the top 20 diseases related to Oppositional Defiant Disorder:



Diseases related to Oppositional Defiant Disorder

Symptoms & Phenotypes for Oppositional Defiant Disorder

UMLS symptoms related to Oppositional Defiant Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

MGI Mouse Phenotypes related to Oppositional Defiant Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 COMT DBH DRD2 DRD4 MAOA SLC6A2
2 homeostasis/metabolism MP:0005376 9.91 COMT DBH DRD2 DRD4 MAOA SLC6A2
3 cardiovascular system MP:0005385 9.87 COMT DBH DRD2 MAOA SLC6A2 SLC6A4
4 integument MP:0010771 9.63 DBH DRD2 SLC6A2 SLC6A3 SLC6A4 TPH2
5 nervous system MP:0003631 9.61 COMT DBH DRD2 DRD4 MAOA SLC6A2
6 taste/olfaction MP:0005394 8.8 DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Oppositional Defiant Disorder

Drugs for Oppositional Defiant Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
5
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
6
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 3007 5826
7
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
8
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
9
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
15 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
19 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
21 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Not Applicable
22 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
23 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Anticonvulsants Phase 4
25 GABA Agents Phase 4
26 Antimanic Agents Phase 4
27 Atomoxetine Hydrochloride Phase 4,Phase 3
28 Adrenergic Agents Phase 4,Phase 3
29 Peripheral Nervous System Agents Phase 4
30 Sympathomimetics Phase 4
31 Autonomic Agents Phase 4
32 Adrenergic alpha-2 Receptor Agonists Phase 4
33 Adrenergic Agonists Phase 4
34 Antihypertensive Agents Phase 4
35 Adrenergic alpha-Agonists Phase 4
36 Dopamine agonists Phase 4,Phase 3,Phase 1,Not Applicable
37 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Not Applicable
38 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Not Applicable
40 Serotonin Receptor Agonists Phase 4,Phase 3,Not Applicable
41 Serotonin Uptake Inhibitors Phase 4
42 Gastrointestinal Agents Phase 4
43 Antiemetics Phase 4
44 insulin Phase 4
45 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Not Applicable
46 Insulin, Globin Zinc Phase 4
47 Lisdexamfetamine Dimesylate Phase 4
48 Anesthetics Phase 4
49 Anesthetics, Local Phase 4
50
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
3 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
4 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Not yet recruiting NCT03781765 Phase 4 Methylphenidate;Atomoxetine
5 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
6 Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD Terminated NCT02638168 Phase 4 Immediate Release Methylphenidate;Placebo
7 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
8 Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder Recruiting NCT02951754 Phase 4 Immediate-release Methylphenidate
9 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
10 Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention Recruiting NCT03279952 Phase 4 CNS Stimulant
11 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
12 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? Completed NCT01127607 Phase 4 lisdexamfetamine
13 A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants Active, not recruiting NCT00756600 Phase 4 Regional Anesthesia;General Anesthesia
14 An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Completed NCT00192023 Phase 3 atomoxetine 0.5 mg/kg/day;placebo;atomoxetine 1.2 mg/kg/day;atomoxetine 1.2-1.4 mg/kg/day
15 Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD Completed NCT00191698 Phase 3 atomoxetine hydrochloride;placebo
16 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
17 Strongest Families Ontario (Formerly the Family Help Program) Completed NCT01473511 Phase 3
18 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
19 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
20 Omega-3 Supplementation and Behavior Problems Completed NCT02334098 Phase 2, Phase 3
21 Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders Completed NCT03627312 Phase 2, Phase 3
22 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
23 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
24 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
25 A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 Edivoxetine
26 Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Completed NCT00402857 Phase 3
27 Brief Strategic Family Therapy for Adolescent Drug Abusers Completed NCT00095303 Phase 3
28 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
29 Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00320528 Phase 3 atomoxetine
30 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
31 Home Based Treatment for Drug Use in Early Adolescents Completed NCT00280228 Phase 2
32 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
33 Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior. Completed NCT00550147 Phase 2 Oros Methylphenidate;quetiapine
34 Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01725737 Phase 2 GlyTI-M;Placebo
35 Evaluating the Efficacy of Supplementation With Micronutrients in ADHD Youth Recruiting NCT03252522 Phase 1, Phase 2
36 Treatment of Conduct Problems and Depression Unknown status NCT01267773 Phase 1
37 Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Completed NCT03292848 Phase 1 Brexpiprazole
38 Treatment of Children With Peer Related Aggressive Behavior (ScouT) Unknown status NCT02143427 Not Applicable
39 Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189 Not Applicable
40 Guided Self-Help for Parents of Children With Externalizing Problem Behavior Unknown status NCT01350986 Not Applicable
41 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Unknown status NCT02707848
42 Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children Unknown status NCT02433145
43 Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT01330849 Not Applicable
44 Better Understand Children and Adolescents' Intrafamilial Oppositional Defiant Disorder Completed NCT03447535
45 Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder Completed NCT00510120 Not Applicable
46 Evaluation of Regulation Focused Psychotherapy for Children Recruiting NCT03594253 Not Applicable
47 Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions Recruiting NCT02409992 Not Applicable
48 Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth Completed NCT00404911 Not Applicable
49 Preschool First Step to Success: An Efficacy Replication Study Active, not recruiting NCT03729154 Not Applicable
50 Mindfulness-based Program for Children With Disruptive Behavior Disorder Active, not recruiting NCT03698240 Not Applicable

Search NIH Clinical Center for Oppositional Defiant Disorder

Genetic Tests for Oppositional Defiant Disorder

Anatomical Context for Oppositional Defiant Disorder

MalaCards organs/tissues related to Oppositional Defiant Disorder:

42
Brain, Testes, Eye, Thyroid, Cortex

Publications for Oppositional Defiant Disorder

Articles related to Oppositional Defiant Disorder:

(show top 50) (show all 298)
# Title Authors Year
1
High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder. ( 30640748 )
2019
2
Emotional valence detection in adolescents with oppositional defiant disorder/conduct disorder or autism spectrum disorder. ( 30680520 )
2019
3
A Comparative Study on the Effectiveness of Individual and Group Play Therapy on Symptoms of Oppositional Defiant Disorder among Children. ( 30625268 )
2019
4
The Parent-Child Relationship and Posttreatment Child Outcomes Across Two Treatments for Oppositional Defiant Disorder. ( 30730774 )
2019
5
Prevalence, comorbidity, functioning and long-term effects of subthreshold oppositional defiant disorder in a community sample of preschoolers. ( 30834986 )
2019
6
The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder. ( 29958238 )
2018
7
Executive Attention and Empathy-Related Responses in Boys with Oppositional Defiant Disorder or Conduct Disorder, With and Without Comorbid Anxiety Disorder. ( 29752662 )
2018
8
Junior temperament character inventory together with quantitative EEG discriminate children with attention deficit hyperactivity disorder combined subtype from children with attention deficit hyperactivity disorder combined subtype plus oppositional defiant disorder. ( 29787785 )
2018
9
Child-based treatment of oppositional defiant disorder: mediating effects on parental depression, anxiety and stress. ( 29948233 )
2018
10
Oppositional defiant disorder/conduct disorder co-occurrence increases the risk of Internet addiction in adolescents with attention-deficit hyperactivity disorder. ( 29865863 )
2018
11
Maltreatment and Affective and Behavioral Problems in Emerging Adults With and Without Oppositional Defiant Disorder Symptoms: Mediation by Parent-Child Relationship Quality. ( 29528803 )
2018
12
Impact of Drug Adherence on Oppositional Defiant Disorder and Conduct Disorder Among Patients With Attention-Deficit/Hyperactivity Disorder. ( 30192445 )
2018
13
Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals. ( 30201120 )
2018
14
Oppositional Defiant Disorder dimensions and aggression: The moderating role of hostile bias and sex. ( 30009747 )
2018
15
Associations of serotonin transporter gene promoter polymorphisms and monoamine oxidase A gene polymorphisms with oppositional defiant disorder in a Chinese Han population. ( 30126429 )
2018
16
Narcissistic traits and self-esteem in children: Results from a community and a clinical sample of patients with oppositional defiant disorder. ( 30142585 )
2018
17
Change in Maternal Stress for Families in Treatment for their Children with Oppositional Defiant Disorder. ( 30294196 )
2018
18
Longitudinal linkages between parenting stress and oppositional defiant disorder (ODD) symptoms among Chinese children with ODD. ( 30321015 )
2018
19
Informant-specific reports of peer and teacher relationships buffer the effects of harsh parenting on children's oppositional defiant disorder during kindergarten. ( 30458890 )
2018
20
External validation of a bifactor model of oppositional defiant disorder. ( 30538308 )
2018
21
Structural Brain Abnormalities of Attention-Deficit/Hyperactivity Disorder With Oppositional Defiant Disorder. ( 28911901 )
2017
22
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial. ( 28213188 )
2017
23
The Mutual Effect of Marital Quality and Parenting Stress on Child and Parent Depressive Symptoms in Families of Children with Oppositional Defiant Disorder. ( 29104548 )
2017
24
Predictors of Partial Hospital Readmission for Young Children with Oppositional Defiant Disorder. ( 29164350 )
2017
25
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2017
26
The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder. ( 28398816 )
2017
27
Sex differences in the associations between vagal reactivity and oppositional defiant disorder symptoms. ( 28573761 )
2017
28
The Characteristics and Age Effects of Emotional Lability in ADHD Children With and Without Oppositional Defiant Disorder. ( 29224418 )
2017
29
Family and Individual Risk and Protective Factors of Depression among Chinese Migrant Children with Oppositional Defiant Disorder Symptoms. ( 28421024 )
2017
30
Age 4 Predictors of Oppositional Defiant Disorder in Early Grammar School. ( 28278601 )
2017
31
Parental involvement as an etiological moderator of middle childhood oppositional defiant disorder. ( 28263622 )
2017
32
Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1-year follow-up intervention study. ( 28181041 )
2017
33
Comparing the characteristics and outcomes of parent- and teacher-reported oppositional defiant disorder: findings from a national sample. ( 29230806 )
2017
34
Oppositional defiant disorder: current insight. ( 29238235 )
2017
35
Multi-Level Family Factors and Affective and Behavioral Symptoms of Oppositional Defiant Disorder in Chinese Children. ( 28713321 )
2017
36
Is emotional dysregulation a risk indicator for auto-aggression behaviors in adolescents with oppositional defiant disorder? ( 27764737 )
2017
37
Oppositional defiant disorder dimensions: genetic influences and risk for later psychopathology. ( 28059443 )
2017
38
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( 28806385 )
2017
39
Risk factors for comorbid oppositional defiant disorder in attention-deficit/hyperactivity disorder. ( 28283834 )
2017
40
Testing Multiple Conceptualizations of Oppositional Defiant Disorder in Youth. ( 28287828 )
2017
41
Executive Function Features in Drug-naive Children with Oppositional Defiant Disorder. ( 28955142 )
2017
42
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( 28225747 )
2017
43
Factors related to the comorbidity between oppositional defiant disorder and anxiety disorders in preschool children. ( 27575516 )
2016
44
Trait and State Variance in Oppositional Defiant Disorder Symptoms: A Multi-Source Investigation With Spanish Children. ( 27148784 )
2016
45
Child Personality Accounts for Oppositional Defiant Disorder Comorbidity Patterns. ( 27233508 )
2016
46
Emotional Regulation and Executive Function Deficits in Unmedicated Chinese Children with Oppositional Defiant Disorder. ( 27247593 )
2016
47
Callous unemotional traits, autism spectrum disorder symptoms and empathy in boys with oppositional defiant disorder or conduct disorder. ( 27575651 )
2016
48
Sex Differences in the Prevalence of Oppositional Defiant Disorder During Middle Childhood: a Meta-Analysis. ( 27282758 )
2016
49
Common Questions About Oppositional Defiant Disorder. ( 27035043 )
2016
50
Association of tryptophan hydroxylase-2 polymorphisms with oppositional defiant disorder in a Chinese Han population. ( 27871272 )
2016

Variations for Oppositional Defiant Disorder

ClinVar genetic disease variations for Oppositional Defiant Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(2;11)(q31;q13.5)pat Translocation Uncertain significance
2 46;XY;t(4;7)(q31;q22)dn Translocation Uncertain significance
3 46;XX;t(2;5)(q33;p15.3) Translocation Uncertain significance

Expression for Oppositional Defiant Disorder

Search GEO for disease gene expression data for Oppositional Defiant Disorder.

Pathways for Oppositional Defiant Disorder

Pathways related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 COMT MAOA SLC6A3 SLC6A4
2
Show member pathways
12.7 COMT DRD2 DRD4 MAOA SLC6A3
3 12.29 COMT DBH TPH2
5 11.92 MAOA SLC6A4 TPH2
6 11.86 SLC6A2 SLC6A3 SLC6A4
7
Show member pathways
11.72 DRD2 MAOA SLC6A3
8 11.69 MAOA SLC6A4 TPH2
9
Show member pathways
11.46 COMT DBH MAOA
10
Show member pathways
11.4 COMT SLC6A2 SLC6A4
11
Show member pathways
11.17 DBH TPH2
12 10.91 DBH SLC6A2
13 10.88 MAOA SLC6A4 TPH2
14
Show member pathways
10.73 DBH MAOA SLC6A2 SLC6A3 SLC6A4 TPH2
15
Show member pathways
10.69 COMT MAOA
16
Show member pathways
10.67 COMT DBH MAOA
17
Show member pathways
10.67 COMT MAOA SLC6A3 SLC6A4
18 10.64 COMT MAOA

GO Terms for Oppositional Defiant Disorder

Cellular components related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.92 COMT DBH DRD2 DRD4 MAOA SLC6A2
2 integral component of plasma membrane GO:0005887 9.77 DRD2 DRD4 SLC6A2 SLC6A3 SLC6A4
3 membrane raft GO:0045121 9.58 SLC6A2 SLC6A3 SLC6A4
4 neuron projection GO:0043005 9.46 SLC6A2 SLC6A3 SLC6A4 TPH2
5 dopaminergic synapse GO:0098691 9.26 DRD2 SLC6A3
6 integral component of presynaptic membrane GO:0099056 9.13 DRD2 SLC6A3 SLC6A4
7 integral component of postsynaptic membrane GO:0099055 8.8 DRD2 SLC6A3 SLC6A4

Biological processes related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.81 DBH DRD4 SLC6A2
2 response to drug GO:0042493 9.72 COMT DRD2 SLC6A2 SLC6A3 SLC6A4
3 locomotory behavior GO:0007626 9.69 DBH DRD2 SLC6A3
4 social behavior GO:0035176 9.65 DRD4 SLC6A4
5 visual learning GO:0008542 9.65 DBH DRD2
6 response to cocaine GO:0042220 9.65 DRD2 SLC6A3
7 response to nicotine GO:0035094 9.64 DRD2 SLC6A3
8 positive regulation of multicellular organism growth GO:0040018 9.63 DRD2 SLC6A3
9 associative learning GO:0008306 9.63 DBH DRD2
10 arachidonic acid secretion GO:0050482 9.62 DRD2 DRD4
11 behavioral response to cocaine GO:0048148 9.62 DRD2 DRD4
12 dopamine receptor signaling pathway GO:0007212 9.61 DRD2 DRD4
13 negative regulation of protein secretion GO:0050709 9.61 DRD2 DRD4
14 neurotransmitter transport GO:0006836 9.61 SLC6A2 SLC6A3 SLC6A4
15 response to iron ion GO:0010039 9.6 DRD2 SLC6A3
16 prepulse inhibition GO:0060134 9.59 DRD2 SLC6A3
17 neurotransmitter biosynthetic process GO:0042136 9.58 SLC6A3 SLC6A4
18 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD4
19 response to amphetamine GO:0001975 9.58 DBH DRD2 DRD4
20 catecholamine metabolic process GO:0006584 9.57 COMT MAOA
21 neurotransmitter catabolic process GO:0042135 9.56 COMT MAOA
22 regulation of dopamine metabolic process GO:0042053 9.55 DRD4 SLC6A3
23 adenohypophysis development GO:0021984 9.54 DRD2 SLC6A3
24 response to pain GO:0048265 9.54 COMT DBH SLC6A2
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.52 DRD2 DRD4
26 fear response GO:0042596 9.49 DBH DRD4
27 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
28 response to histamine GO:0034776 9.46 DRD2 DRD4
29 dopamine metabolic process GO:0042417 9.43 COMT DRD2 DRD4
30 behavioral response to ethanol GO:0048149 9.33 DBH DRD2 DRD4
31 monoamine transport GO:0015844 9.13 SLC6A2 SLC6A3 SLC6A4
32 dopamine catabolic process GO:0042420 8.92 COMT DBH MAOA SLC6A3

Molecular functions related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 symporter activity GO:0015293 9.61 SLC6A2 SLC6A3 SLC6A4
2 drug binding GO:0008144 9.54 DRD2 DRD4 SLC6A3
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD4
4 neurotransmitter:sodium symporter activity GO:0005328 9.33 SLC6A2 SLC6A3 SLC6A4
5 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD4
6 dopamine:sodium symporter activity GO:0005330 9.26 SLC6A2 SLC6A3
7 dopamine binding GO:0035240 9.13 DRD2 DRD4 SLC6A3
8 monoamine transmembrane transporter activity GO:0008504 8.8 SLC6A2 SLC6A3 SLC6A4
9 metal ion binding GO:0046872 10 COMT DBH DRD4 SLC6A2 SLC6A3 SLC6A4

Sources for Oppositional Defiant Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....